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Abstract: Statin therapy has become one of the most widely prescribed medications in the world because of its efficacy 
in the primary and secondary prevention of cardiovascular mortality and stroke. Current cardiovascular guidelines 
recommend statin use in all patients with stroke due to atherosclerosis (non-cardioembolic stroke). Statin therapy at 
stroke onset is associated with good functional outcome and reduced risk of cardiovascular events after stroke via 
different mechanisms. These include lipid-lowering effects, platelet aggregation, improved endothelial function, anti-
inflammation activity, neuroprotective action, and stabilization of atherosclerotic plaques. Nevertheless, the effects of 
statin therapy following major stroke are uncertain and data on the optimal dose and intensity are limited. Statins may 
potentially increase the incidence of overall stroke and fatal stroke in patients with a history of renal transplantation, or 
regular hemodialysis. There is a need for additional studies since statins benefits do not extend across all etiologic 
subtypes of ischemic stroke: they are indicated for thrombotic strokes and some, but not all, lacunar, cardioembolic or 
essential strokes, and they are not suitable for ischemic strokes of unusual etiology. 
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INTRODUCTION 
In the last decade, statin therapy has revolutionized 
the management of vascular diseases since becoming 
one of the most commonly prescribed medications in 
the world, because of its potent cardio-protective 
effects on both primary and secondary stroke 
prevention [1]. Statin therapy reduces the risk of 
cardiovascular events after stroke via different 
mechanisms. These include lipid-lowering effects, 
platelet aggregation, improved endothelial function, 
anti-inflammation activity, neuroprotective action, and 
stabilization of atherosclerotic plaques [2-6]. 
Stroke is a heterogeneous syndrome with multiple 
underlying pathologies such as atherosclerotic large 
vessel disease, small vessel disease, cardioembolic 
stroke, stroke of unusual etiologies and cerebral 
ischemia of undetermined etiology [7]. Large vessel 
disease due to atherosclerosis is more likely to have an 
association with raised LDL and total cholesterol. 
Consequently, statin therapy is expected to be more 
beneficial in those with atherosclerosis [1-8]. 
The Stroke Prevention by Aggressive Reduction in 
Cholesterol Levels (SPARCL) trial evaluated the effect 
of statins in secondary prevention of stroke and  
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reported 16% lower risk of recurrent stroke (11.2% 
versus 13.1%) with 80 mg of atorvastatin daily, 
compared with placebo in noncardioembolic stroke or 
TIA (patients with large and small vessel disease). It 
was the first trial to evaluate the effect of statin in 
secondary prevention of stroke. The risk of 
hemorrhagic stroke was significantly higher in the statin 
group (HR: 2.4), in men (HR: 1.79) and increased by 
age (HR: 1.42 per 10-year increment) but not 
significantly in fatal hemorrhagic stroke [9]. 
Myotoxicity or hepatic toxicity is a cause of potential 
adverse effects of statin therapy that may limit daily 
activities. Caution in patients with a history of liver 
disease or high alcohol intake, a past or family history 
of muscular disorders, previous muscular toxicity, renal 
impairment, and hypothyroidism is mandatory. Routine 
monitoring of liver profile and CK levels at 3 and 12 
months is recommended [1]. 
META-ANALYSIS 
Early clinical studies suggested potential 
effectiveness of statins in ischemic stroke patients with 
better early outcome (reduced mortality during 
hospitalization and neurological disability at hospital 
discharge) [10, 11]. This reinforced the promising 
results reported in pioneer studies in experimental 
animal models [1]. Later, favorable outcomes of statins 
therapy in cerebral ischemia were definitively confirmed 
by the results of two meta-analyses performed in 
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experimental stroke animal models. Both the study of 
García-Bonilla et al. [12] and Baryan et al. [13] clearly 
demonstrated the effectiveness of statins and their 
neuroprotective role in experimental ischemia (Table 
1). 
The impact of statins therapy in cerebral ischemia in 
humans (Table 1) was consolidated by the results of 
different meta-analysis that showed the beneficial 
aspects although some negative or neutral effects were 
presented concurrently. The meta-analysis conducted 
by Cordenier et al. [14] indicated that prestroke statins 
use was associated with a decreased in-hospital 
mortality, but did not influence the 3 month functional 
outcomes. NiChróinin et al. [15] reported that statin 
therapy at stroke onset was associated with good 
functional outcome although warned that caution 
should be taken in patients receiving thrombolytic 
therapy. Naci et al. [16] found that statins were 
effective in reducing the incidence of non-fatal strokes 
but not of fatal ones. Wang et Zhang [17] reported a 
decline in the incidence of fatal and hemorrhagic 
strokes but an increased risk in renal transplant 
patients and those undergoing regular hemodialysis. 
GUIDELINES 
Current international guidelines for management of 
acute ischemic stroke recommend statin use in all 
patients with stroke due to atherosclerosis (non-
Table 1: Meta-Analysis of the Efficacy of Statins in Acute Stroke 
Author, year Title (number of studies) Results 
Cordenier et al. [7], 
(2011)* 
“Pre-stroke use of statins on stroke 
outcomes: a meta-analysis of observational 
studies” 
(11 studies) 
Pre-treatment with statins decreases in-hospital mortality 
Increases the risk of developing a symptomatic hemorrhagic 
transformation in patients treated with thrombolysis. 
Statins do not influence the 3 month functional outcomes as 
measured with the mRS. 
García-Bonilla L et al. 
[11], (2012)** 
“Evidence for the efficacy in animal stroke 
models: a meta-analysis” 
(41 publications) 
Reinforces the value of statin treatment in cerebral ischemia 
By type of statin, simvastatin presents greater infarct size 
reduction. 
The estimated effect is higher when statins are given as pre-
treatment rather than post-treatment 
Effectiveness is greater when drug is given orally. 
Higher doses better than lower doses 
Baryan HK et al. [14], 
(2012)** 
“Systematic review and meta-analysis of the 
efficacy of statins in experimental stroke” 
Effect of statins in animal models of focal 
cerebral ischemia 
(18 published studies) 
Statins administered after middle cerebral artery occlusion have 
modest efficacy. 
Statins administered after the onset of experimental ischemia are 
neuroprotective 
NíChróinín DN et al. 
[15], (2013)* 
“Statin therapy and outcome after ischemic 
stroke” 
(27 studies) 
Statin treatment at stroke onset is associated with good functional 
outcome at 90 days but not at 1 year and with reduced fatality at 
90 days and 1 year. 
In the studies restricted to thrombolysis-treated patients, an 
association between statins and increased fatality at 90 days is 
observed. However this association was no longer present after 
adjusting for age and stroke severity. 
Naci H et al. [16], 
(2013)* 
“Comparative effects of statins on major 
cerebrovascular events: a multiple-treatments 
meta-analysis of placebo-controlled and 
active comparator trials” 
(61 trials) 
Statins are significantly more effective than control in reducing 
major cerebrovascular events. 
Considering individual statins, significant reduction is achieved by 
atorvastatin, pravastatin and simvastatin as compared with control 
on major cerebrovascular events. 
Statins lead to significant reductions in the risk of non-fatal strokes 
but not of fatal ones. 
Wang W and Zhang 
B. [19], (2014)* 
“Statins for the prevention of stroke: a meta-
analysis of randomized controlled trials” 
(18 randomized controlled trials) 
Statins reduce the overall incidence of stroke more than placebo. 
In particular statins show efficacy in reducing the incidence of fatal 
and hemorrhagic stroke. 
Statins increase the overall incidence of stroke and fatal stroke in 
renal transplant recipients and patients undergoing regular 
hemodialysis 
*Clinical studies; ** Experimental studies. 
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cardioembolic stroke). For instance, the 
recommendations of the Catalan Neurology Society 
[18] agree with the 2013 American College of 
Cardiology and American Heart Association treatment 
guideline [19], that recommends intensive statin 
therapy for all patients <75 years old with 
atherosclerotic cardiovascular disease including 
ischemic stroke patients. 
The European Guidelines on cardiovascular 
disease prevention in clinical practice [20] recommend 
the use of statin therapy in patients with non-
cardioembolic ischemic stroke or TIA, but statins 
should be avoided after a hemorrhagic stroke except in 
the event of concurrent high vascular risk. 
MORE EVIDENCES AND CONTROVERSIES 
A benefit of statins given pre as well as after stroke 
onset was seen with a greater magnitude effect with 
poststroke statins in the Dublin study [1, 21]. Statin 
withdrawal in acute stroke has been associated with 
worse outcomes in terms of dependency and 
neurological impairment and hence, treatment should 
be continued, except in the event of hemorrhagic 
stroke. 
However, the effects of statin therapy following 
major stroke remain uncertain and there are conflicting 
data on outcomes of patients receiving combination 
therapy with statins and tPA. Statin use at stroke onset 
may be associated with increased rates of symptomatic 
intracerebral hemorrhage after intravenous or intra-
arterial thrombolysis possibly mediated via 
antithrombotic effects of statins on endothelium, 
leucocytes and platelets, and increased levels of 
endogenous tPA [15]. 
Furthermore, data on the optimal dose are limited 
and little is known about comparison of high-intensity 
versus low/moderate intensity therapy in clinical stroke 
subgroups. Some authors suggest that cerebrovascular 
patients should receive intensive therapy (atorvastatin 
40-80 mg or rosuvastatin 20-40 mg), but other statins 
seemed to be not so effective [22, 23]. 
Some of these questions have been answered by 
the PROSPER study recently published [24]. This 
study analyzed a sample of 77,468 ischemic stroke 
patients statin-naïve at the time of admission, 
discharged alive from 2007 to 2011. Of them, 54,991 
(71%) were prescribed statin therapy at discharge. 
Statin therapy was associated with a 9% lower hazard 
of major adverse cardiac events, 28 more days of 
home time, a 16% lower hazard of mortality and a 7% 
lower hazard of all-cause readmission in the 2-year 
post-discharge period; 30.9% were prescribed high-
intensity statin therapy at discharge (atorvastatin 
>40mg, rosuvastatin >20mg, simvastatin 80mg or 
simvastatin/ezetimibe 10/80mg). Compared with 
patients who were prescribed low/moderate intensity 
statins (all other statin agents/doses) there were no 
statistically significant differences in clinical outcomes 
in the 2 years following discharge. No evidence of 
increased risk of hemorrhagic stroke among statin 
users was found [24]. 
Little is known about the role of ezetimibe in stroke 
prevention. A clinical trial reported that reduction of 
LDL cholesterol with simvastatin 20 mg plus ezetimibe 
10 mg daily, safely reduced the incidence of major 
atherosclerotic events in a wide range of patients with 
advanced chronic kidney disease [25]. In PROSPER 
study, the simvastatin/ezetimibe (10/80mg) subgroup 
was included in the high-intensity statin therapy group 
and no evidence in clinical outcomes was observed 
when compared to the non-high intensity group [24]. 
STATIN THERAPY IN THE DIFFERENT ISCHEMIC 
STROKE SUBTYPES 
Some authors consider that benefits of statins 
extend across all stroke types including cardioembolic 
stroke [4]. Because most patients survive stroke and 
die later from myocardial infarction rather than from 
another stroke or non-vascular disease, stroke patients 
contribute highly to cardiac deaths. For this reason, it is 
considered very important to use statin therapy for all 
stroke patients [1]. However, this statement is 
inaccurate by the fact that not all stroke subtypes are 
related to an atherosclerotic mechanism. Thus, most of 
cerebral infarcts of unusual etiology are due to 
hematologic diseases (like polycythemia vera, essential 
thrombocytemia, protein C deficiency, etc.), to 
inflammatory arteritis (for example, Horton arteritis), to 
migraine stroke or to arterial dissection [26] and, in 
these cases, statin therapy is not suitable. Likewise, in 
cerebral embolisms due to patent foramen ovale, in 
rheumatic valvular diseases or mitral valve prolapse, to 
cite just a few, the statins benefit does not appear to be 
convincing. Strokes of undetermined cause are an 
etiological subtype wherein statin therapy is 
controversial. Nonetheless, within that subtype, 
complex aortic atheroma is an emerging cause of 
cerebral ischemia which requires a high clinical 
suspicion [27-29], and once diagnosed, statin therapy 
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would then be indicated. Finally, it would be interesting 
to perform a study in the subgroup of patients with 
lacunar cerebral infarctions: possibly, in patients 
suffering from microatheromatosis statin therapy might 
be useful but in those suffering from lipohyalinosis, 
statins prescription would not be therapeutically 
justified [30, 31]. Therefore, the statement that 
irrespective of the etiology of ischemic stroke, use of 
statins has been associated with favourable outcomes 
is not accurate, being vague and generic. Statins 
should be avoided in strokes of unusual case. 
CONCLUSIONS 
Statin therapy at stroke onset is associated with 
good functional outcomes. Effects of statins in 
secondary prevention of ischemic stroke are beneficial, 
but there were not statistically significant in the 
prevention of fatal stroke. Moreover, statins may 
potentially increase the incidence of overall stroke and 
fatal stroke in patients with a history of renal 
transplantation, or regular hemodialysis. The benefits 
of statin therapy differ depending on the stroke 
subtype: provide maximum effectiveness in 
atherothrombotic stroke and may play a useful role in 
patients with lacunar, cardioembolic or essential 
strokes, but should be avoided in strokes of unusual 
cause. Furthermore, no real advantages are noted with 
the use of high-intensity statin doses compared to 
low/moderate intensity statin use for ischemic stroke 
prevention. Randomized trials and individual-patient 
data from large registries will be required to resolve 
these issues. 
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